This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database.
NIHR HSRIC. Nivolumab (Opdivo) for stage IV or recurrent PD-L1 positive non-small cell lung cancer – first line. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2016
Non-small cell lung cancer is the most common type of lung cancer. It is often diagnosed late and is difficult to treat once it has spread to other parts of the body.
Nivolumab is a new drug for the treatment of a specific type of non-small cell lung cancer. It is given as a drip into a vein once every two weeks. Some studies have suggested nivolumab may be used as a first line treatment and helpful for people who have non-small cell lung cancer that has spread to other parts of the body. Studies are currently ongoing to see how well nivolumab works and how safe it is to use.
If nivolumab is licensed for use in the UK, it could be a new treatment option for patients with advanced non-small cell lung cancer, which may improve survival and cause fewer side effects than current treatments (usually chemotherapy).
Subject indexing assigned by CRD
Antibodies, Monoclonal; Antigens, CD274; Carcinoma, Non-Small-Cell Lung; Humans; Neoplasm Recurrence, Local
Country of organisation
An English language summary is available.
Address for correspondence
NIHR Horizon Scanning Research&Intelligence Centre, University of Birmingham, Institute of Applied Health Research, Public Health building, Edgbaston, Birmingham B15 2TT
Tel: 0121 414 9077 Email: email@example.com
Date abstract record published